Pfizer Announces Study Of Oral COVID-19 Drug | The Daily Wire
Although in this case, the treatment sounds a lot more dangerous than the vaccine.
The clinical candidate, PF-07321332, is a “protease inhibitor with potent anti-viral activity against SARS-CoV-2.” Protease inhibitors attach to a viral enzyme (named a protease) and prohibit the virus from replicating in a cell. The company’s statement adds that such inhibitors have been successful in the past “at treating other viral pathogens such as HIV and hepatitis C virus, both alone and in combination with other antivirals.”
What else does it prevent from happening in your body? Or allow to happen in greater amounts than you’d like? Questions, questions.
No comments:
Post a Comment